Andere Sprachen Theralase Technologies Inc.

Aktien

A0DLB7

CA88337V1004

TLT

Markt geschlossen - Toronto S.E. Andere Börsenplätze 21:50:24 28.06.2024			% 5 Tage	% 1. Jan.
0,21 ^CAD	+10,53 %		+13,51 %	+20,00 %

20.06.	Theralase Technologies Inc. gibt bekannt, dass Rutherrin Nicht-Krebs-Medikamente für die Krebstherapie umwidmet	CI
12.06.	Theralase Technologies Inc. gibt bekannt, dass Rutherrin die Wirksamkeit von Chemotherapien erhöht	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Theralase Technologies Inc. Announces Rutherrin Repurposes Non-Cancer Drugs for Cancer Therapy	20.06.
Theralase Technologies Inc. Announces Rutherrin Increases Efficacy of Chemotherapy	12.06.
Theralase Technologies Inc. Announces Ruvidar Enhances Efficacy of Cancer Drug	10.06.
Theralase Technologies Inc. Successfully Destroys Lung Cancer	06.06.
Theralase® Technology Effective in Virus Inactivation	04.06.
Theralase Technologies Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	30.05.
Theralase Technologies Inc. announced that it has received CAD 0.7502 million in funding	24.04.
Theralase Technologies Inc. Receives Canadian Cancer Vaccine Patent	05.04.
Theralase Technologies Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.03.
Theralase Technologies Donates Cool Laser Therapy Technology to Aid in R&D of Treatment for Parkinson's Disease	12.02.
Theralase Technologies shares update on Phase II Bladder Cancer study	08.02.
Theralase Technologies Closes C$1.2-Million Private Placement of Share Units	05.02.
Theralase Technologies Inc. announced that it has received CAD 1.200001 million in funding	05.02.
Theralase Technologies Provides Update on Phase II Bladder Cancer Clinical Study	15.01.
Theralase Technologies Inc. Provides Update on Phase II Bladder Cancer Clinical Study	15.01.
Theralase makes positive progress on Phase II study on bladder cancer; targets breakthrough designation with FDA	04.12.
Theralase Technologies Raises C$1.17 Million in a Private Placement of Share Units	29.11.
Theralase Technologies Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29.11.
Theralase Technologies Inc. announced that it has received CAD 1.17 million in funding	29.11.
Theralase Technologies Raising up to C$1.5 Million in a Private Placement of Share Units	17.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Theralase Technologies Inc.

Aktien

A0DLB7

CA88337V1004

TLT

Andere Sprachen

Filter